IGC Pharma Considers Legal Action After Short Seller's Fraud Conviction
Potomac, Wednesday, 29 July 2026.
Following short seller Andrew Left’s federal fraud conviction, IGC Pharma is evaluating legal remedies to recover damages from a 2018 short-selling campaign that wiped out significant shareholder value.
IGC Pharma Assessing Legal Remedies Following Fraud Verdict
On July 29, 2026, IGC Pharma (NYSE American: IGC) confirmed it is evaluating potential civil remedies after a federal jury found short seller Andrew Left guilty of securities fraud [1]. The company announced on July 28, 2026, that it is reviewing the federal indictment and jury verdict in United States v. Andrew Left to determine if claims for recoverable damages exist [1]. This legal assessment comes eight years after a 2018 short-selling campaign targeted the company, then known as India Globalization Capital, Inc. [1]. The Board of Directors is currently examining whether the company suffered harm to market value, reputational damage, and regulatory costs stemming from the campaign [1]. Ram Mukunda, Chief Executive Officer of IGC Pharma, stated that shareholders have questioned the 2018 events for years and the company is now evaluating available remedies to protect shareholder interests [1].
Financial Impact of the 2018 Short Campaign
Federal indictment details allege that the short campaigns targeting IGC and another issuer generated significant profits for the involved parties [1]. Specifically, the campaign generated over $3.8 million in profits for a hedge fund and over $1.1 million for Andrew Left [1]. The total combined profits for the hedge fund and Left from these activities amount to 4.9 million according to the indictment figures [1]. In a related settled SEC administrative proceeding, Anson Funds Management LP and Anson Advisors Inc. agreed to pay a short publisher a share of profits from trading around a bearish tweet concerning IGC [1]. AIMF’s short positions on the day of that tweet generated approximately $500,000 in trading profits [1]. Anson Funds Management LP and Anson Advisors Inc. subsequently agreed to pay $2.25 million in combined civil monetary penalties to settle SEC findings without admitting or denying them [1].
Clinical Progress Amidst Legal Review
While reviewing legal options, IGC Pharma continues to advance its biomedical pipeline, specifically its Phase 2 clinical trials for Alzheimer’s disease treatments [1]. The company is focused on the Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia [1]. Additionally, the development pipeline includes TGR-63, though no specific completion date was provided for the CALMA trial in the recent announcement [1]. There is no specified deadline for the Board’s decision on pursuing legal claims, leaving the timeline for potential litigation indeterminate [1]. The company maintains that the public record now describes conduct warranting serious review as it balances operational advancements with historical accountability [1].